Novartis Takes $1.9 Billion Write-Down After Rare-Disease Drug Trial Setback
The Novartis Q3 2026 results show a $1.9 billion del-desiran impairment yet a raised outlook. Here is how the three fit together.
The Novartis Q3 2026 results show a $1.9 billion del-desiran impairment yet a raised outlook. Here is how the three fit together.